Aptamers are oligonucleotide sequences with a length of about 25–80 bases which have
abilities to bind to specific target molecules that rival those of monoclonal antibodies. They …

With the development of proteomics and epigenetics, a large number of RNA‐binding
proteins (RBPs) have been discovered in recent years, and the interaction between long …

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

The first therapeutic nucleic acid, a DNA oligonucleotide, was approved for clinical use in
1998. Twenty years later, in 2018, the first therapeutic RNA-based oligonucleotide was …

Emerging therapeutics that utilize RNA interference (RNAi) have the potential to treat broad
classes of diseases due to their ability to reversibly silence target genes. In August 2018, the …

Nucleic acid aptamers, often termed'chemical antibodies', are functionally comparable to
traditional antibodies, but offer several advantages, including their relatively small physical …

Precision medicine holds great promise to harness genetic and epigenetic cues for targeted
treatment of a variety of diseases, ranging from many types of cancers, neurodegenerative …

The oligonucleotide therapeutics field has seen remarkable progress over the last few years
with the approval of the first antisense drug and with promising developments in late stage …

The RNA interference (RNAi) pathway possesses immense potential in silencing any gene
in human cells. Small interfering RNA (siRNA) can efficiently trigger RNAi silencing of …

Functional nucleic acid (NA)-based drugs have a broad range of applications since they
allow the alteration and control of gene/protein expression patterns in cells. In principle …